Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Aegis Comments on FDA 510(k) Approval of Bausch + Lomb's VICTUS (VRX)
July 17, 2014 9:56 AM UTCAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following news earlier that the company's wholly-owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the FDA for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.
Analyst Ram Selvaraju commented, In our view, this approval demonstrates the growth potential of the Bausch + Lomb product portfolio and also showcases Valeant's continued commitment to launching new products in high-growth,... More
